APO Research
Talk to an analyst

APO RESEARCH · REPORT

Meningioma Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Meningioma Drug Market Outlook and Growth Opportunities 2026

22 December 2025191 pages

Choose your research edition.

Industry ResearchMeningioma Drug Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Meningioma Drug Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Meningioma Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Meningioma Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Meningioma Drug Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Meningioma Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Meningioma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Meningioma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Meningioma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Meningioma Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Meningioma Drug market include Arno Therapeutics Inc, Boehringer Ingelheim GmbH, Genentech Inc, Merck KGaA, Ono Pharmaceutical Co Ltd, Pharma Mar SA, Progenics Pharmaceuticals Inc, AstraZeneca Plc and GlaxoSmithKline Plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Meningioma Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Meningioma Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Meningioma Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Meningioma Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Meningioma Drug Segment by Company

Arno Therapeutics Inc

Boehringer Ingelheim GmbH

Genentech Inc

Merck KGaA

Ono Pharmaceutical Co Ltd

Pharma Mar SA

Progenics Pharmaceuticals Inc

AstraZeneca Plc

GlaxoSmithKline Plc

Eli Lilly and Co

Merck & Co Inc

Novartis AG

Meningioma Drug Segment by Type

Avelumab

AR-42

Afatinib Dimaleate

Abemaciclib

Others

Meningioma Drug Segment by Application

Hospital

Clinic

Others

Meningioma Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Meningioma Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Meningioma Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Meningioma Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Meningioma Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningioma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Meningioma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningioma Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Meningioma Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Meningioma Drug industry.

Chapter 3: Detailed analysis of Meningioma Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Meningioma Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Meningioma Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Meningioma Drug Industry Trends Table 2. Meningioma Drug Industry Drivers Table 3. Meningioma Drug Industry Opportunities and Challenges Table 4. Meningioma Drug Industry Restraints Table 5. Global Meningioma Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Meningioma Drug Revenue Share by Company (2021-2026) Table 7. Global Meningioma Drug Sales Volume by Company (k units) & (2021-2026) Table 8. Global Meningioma Drug Sales Volume Share by Company (2021-2026) Table 9. Global Meningioma Drug Average Price (US$/unit) of Company (2021-2026) Table 10. Global Meningioma Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Meningioma Drug Key Company Manufacturing Base & Headquarters Table 12. Global Meningioma Drug Company, Product Type & Application Table 13. Global Meningioma Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Meningioma Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Avelumab Table 18. Significant Companies of AR-42 Table 19. Significant Companies of Afatinib Dimaleate Table 20. Significant Companies of Abemaciclib Table 21. Significant Companies of Others Table 22. Global Meningioma Drug Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Meningioma Drug Sales Volume by Type (2021-2026) & (k units) Table 24. Global Meningioma Drug Sales Volume by Type (2027-2032) & (k units) Table 25. Global Meningioma Drug Sales Volume Share by Type (2021-2026) Table 26. Global Meningioma Drug Sales Volume Share by Type (2027-2032) Table 27. Global Meningioma Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Meningioma Drug Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Meningioma Drug Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Meningioma Drug Sales Value Share by Type (2021-2026) Table 31. Global Meningioma Drug Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Hospital Table 33. Significant Companies of Clinic Table 34. Significant Companies of Others Table 35. Global Meningioma Drug Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Meningioma Drug Sales Volume by Application (2021-2026) & (k units) Table 37. Global Meningioma Drug Sales Volume by Application (2027-2032) & (k units) Table 38. Global Meningioma Drug Sales Volume Share by Application (2021-2026) Table 39. Global Meningioma Drug Sales Volume Share by Application (2027-2032) Table 40. Global Meningioma Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Meningioma Drug Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Meningioma Drug Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Meningioma Drug Sales Value Share by Application (2021-2026) Table 44. Global Meningioma Drug Sales Value Share by Application (2027-2032) Table 45. Global Meningioma Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global Meningioma Drug Sales by Region (2021-2026) & (k units) Table 47. Global Meningioma Drug Sales Market Share by Region (2021-2026) Table 48. Global Meningioma Drug Sales by Region (2027-2032) & (k units) Table 49. Global Meningioma Drug Sales Market Share by Region (2027-2032) Table 50. Global Meningioma Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Meningioma Drug Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Meningioma Drug Sales Value Share by Region (2021-2026) Table 53. Global Meningioma Drug Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Meningioma Drug Sales Value Share by Region (2027-2032) Table 55. Global Meningioma Drug Market Average Price (US$/unit) by Region (2021-2026) Table 56. Global Meningioma Drug Market Average Price (US$/unit) by Region (2027-2032) Table 57. Global Meningioma Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Global Meningioma Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Meningioma Drug Sales by Country (2021-2026) & (k units) Table 60. Global Meningioma Drug Sales Market Share by Country (2021-2026) Table 61. Global Meningioma Drug Sales by Country (2027-2032) & (k units) Table 62. Global Meningioma Drug Sales Market Share by Country (2027-2032) Table 63. Global Meningioma Drug Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Meningioma Drug Sales Value Market Share by Country (2021-2026) Table 65. Global Meningioma Drug Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Meningioma Drug Sales Value Market Share by Country (2027-2032) Table 67. Arno Therapeutics Inc Company Information Table 68. Arno Therapeutics Inc Business Overview Table 69. Arno Therapeutics Inc Meningioma Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. Arno Therapeutics Inc Meningioma Drug Product Portfolio Table 71. Arno Therapeutics Inc Recent Development Table 72. Boehringer Ingelheim GmbH Company Information Table 73. Boehringer Ingelheim GmbH Business Overview Table 74. Boehringer Ingelheim GmbH Meningioma Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Boehringer Ingelheim GmbH Meningioma Drug Product Portfolio Table 76. Boehringer Ingelheim GmbH Recent Development Table 77. Genentech Inc Company Information Table 78. Genentech Inc Business Overview Table 79. Genentech Inc Meningioma Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Genentech Inc Meningioma Drug Product Portfolio Table 81. Genentech Inc Recent Development Table 82. Merck KGaA Company Information Table 83. Merck KGaA Business Overview Table 84. Merck KGaA Meningioma Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Merck KGaA Meningioma Drug Product Portfolio Table 86. Merck KGaA Recent Development Table 87. Ono Pharmaceutical Co Ltd Company Information Table 88. Ono Pharmaceutical Co Ltd Business Overview Table 89. Ono Pharmaceutical Co Ltd Meningioma Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Ono Pharmaceutical Co Ltd Meningioma Drug Product Portfolio Table 91. Ono Pharmaceutical Co Ltd Recent Development Table 92. Pharma Mar SA Company Information Table 93. Pharma Mar SA Business Overview Table 94. Pharma Mar SA Meningioma Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Pharma Mar SA Meningioma Drug Product Portfolio Table 96. Pharma Mar SA Recent Development Table 97. Progenics Pharmaceuticals Inc Company Information Table 98. Progenics Pharmaceuticals Inc Business Overview Table 99. Progenics Pharmaceuticals Inc Meningioma Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Progenics Pharmaceuticals Inc Meningioma Drug Product Portfolio Table 101. Progenics Pharmaceuticals Inc Recent Development Table 102. AstraZeneca Plc Company Information Table 103. AstraZeneca Plc Business Overview Table 104. AstraZeneca Plc Meningioma Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. AstraZeneca Plc Meningioma Drug Product Portfolio Table 106. AstraZeneca Plc Recent Development Table 107. GlaxoSmithKline Plc Company Information Table 108. GlaxoSmithKline Plc Business Overview Table 109. GlaxoSmithKline Plc Meningioma Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. GlaxoSmithKline Plc Meningioma Drug Product Portfolio Table 111. GlaxoSmithKline Plc Recent Development Table 112. Eli Lilly and Co Company Information Table 113. Eli Lilly and Co Business Overview Table 114. Eli Lilly and Co Meningioma Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. Eli Lilly and Co Meningioma Drug Product Portfolio Table 116. Eli Lilly and Co Recent Development Table 117. Merck & Co Inc Company Information Table 118. Merck & Co Inc Business Overview Table 119. Merck & Co Inc Meningioma Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 120. Merck & Co Inc Meningioma Drug Product Portfolio Table 121. Merck & Co Inc Recent Development Table 122. Novartis AG Company Information Table 123. Novartis AG Business Overview Table 124. Novartis AG Meningioma Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 125. Novartis AG Meningioma Drug Product Portfolio Table 126. Novartis AG Recent Development Table 127. Key Raw Materials Table 128. Raw Materials Key Suppliers Table 129. Meningioma Drug Distributors List Table 130. Meningioma Drug Customers List Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. Meningioma Drug Product Image Figure 2. Global Meningioma Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Meningioma Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Meningioma Drug Sales (2021-2032) & (k units) Figure 5. Global Meningioma Drug Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Meningioma Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Avelumab Image Figure 10. AR-42 Image Figure 11. Afatinib Dimaleate Image Figure 12. Abemaciclib Image Figure 13. Others Image Figure 14. Global Meningioma Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Meningioma Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Meningioma Drug Sales Volume Share by Type (2021-2032) Figure 17. Global Meningioma Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Meningioma Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Meningioma Drug Sales Value Share by Type (2021-2032) Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Others Image Figure 23. Global Meningioma Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Meningioma Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Meningioma Drug Sales Volume Share by Application (2021-2032) Figure 26. Global Meningioma Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Meningioma Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Meningioma Drug Sales Value Share by Application (2021-2032) Figure 29. Global Meningioma Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 30. Global Meningioma Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Meningioma Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Meningioma Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Meningioma Drug Sales Value (2021-2032) & (US$ Million) Figure 34. North America Meningioma Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Meningioma Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Meningioma Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Meningioma Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Meningioma Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Meningioma Drug Sales Value (2021-2032) & (US$ Million) Figure 40. South America Meningioma Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Meningioma Drug Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Meningioma Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Meningioma Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Meningioma Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Meningioma Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Meningioma Drug Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Meningioma Drug Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Avelumab
  • AR-42
  • Afatinib Dimaleate
  • Abemaciclib
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Arno Therapeutics Inc
  • Boehringer Ingelheim GmbH
  • Genentech Inc
  • Merck KGaA
  • Ono Pharmaceutical Co Ltd
  • Pharma Mar SA
  • Progenics Pharmaceuticals Inc
  • AstraZeneca Plc
  • GlaxoSmithKline Plc
  • Eli Lilly and Co
  • Merck & Co Inc
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Meningioma Drug Sales Value (2021-2032)
  4. 1.2.2 Global Meningioma Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Meningioma Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Meningioma Drug Market Dynamics
  1. 2.1 Meningioma Drug Industry Trends
  2. 2.2 Meningioma Drug Industry Drivers
  3. 2.3 Meningioma Drug Industry Opportunities and Challenges
  4. 2.4 Meningioma Drug Industry Restraints
3 Meningioma Drug Market by Company
  1. 3.1 Global Meningioma Drug Company Revenue Ranking in 2025
  2. 3.2 Global Meningioma Drug Revenue by Company (2021-2026)
  3. 3.3 Global Meningioma Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Meningioma Drug Average Price by Company (2021-2026)
  5. 3.5 Global Meningioma Drug Company Ranking (2024-2026)
  6. 3.6 Global Meningioma Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Meningioma Drug Company Product Type and Application
  8. 3.8 Global Meningioma Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Meningioma Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Meningioma Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Meningioma Drug Market by Type
  1. 4.1 Meningioma Drug Type Introduction
  2. 4.1.1 Avelumab
  3. 4.1.2 AR-42
  4. 4.1.3 Afatinib Dimaleate
  5. 4.1.4 Abemaciclib
  6. 4.1.5 Others
  7. 4.2 Global Meningioma Drug Sales Volume by Type
  8. 4.2.1 Global Meningioma Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Meningioma Drug Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Meningioma Drug Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Meningioma Drug Sales Value by Type
  12. 4.3.1 Global Meningioma Drug Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Meningioma Drug Sales Value by Type (2021-2032)
  14. 4.3.3 Global Meningioma Drug Sales Value Share by Type (2021-2032)
5 Meningioma Drug Market by Application
  1. 5.1 Meningioma Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Meningioma Drug Sales Volume by Application
  6. 5.2.1 Global Meningioma Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Meningioma Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Meningioma Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Meningioma Drug Sales Value by Application
  10. 5.3.1 Global Meningioma Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Meningioma Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Meningioma Drug Sales Value Share by Application (2021-2032)
6 Meningioma Drug Regional Sales and Value Analysis
  1. 6.1 Global Meningioma Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Meningioma Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Meningioma Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Meningioma Drug Sales by Region (2027-2032)
  5. 6.3 Global Meningioma Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Meningioma Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Meningioma Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Meningioma Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Meningioma Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Meningioma Drug Sales Value (2021-2032)
  12. 6.6.2 North America Meningioma Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Meningioma Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Meningioma Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Meningioma Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Meningioma Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Meningioma Drug Sales Value (2021-2032)
  21. 6.9.2 South America Meningioma Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Meningioma Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Meningioma Drug Sales Value Share by Country, 2025 VS 2032
7 Meningioma Drug Country-level Sales and Value Analysis
  1. 7.1 Global Meningioma Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Meningioma Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Meningioma Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Meningioma Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Meningioma Drug Sales by Country (2027-2032)
  6. 7.4 Global Meningioma Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Meningioma Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Meningioma Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Meningioma Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Meningioma Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Meningioma Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Meningioma Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Meningioma Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Meningioma Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Meningioma Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Meningioma Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Meningioma Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Meningioma Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Meningioma Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Meningioma Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Meningioma Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Meningioma Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Meningioma Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Meningioma Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Meningioma Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Meningioma Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Meningioma Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Meningioma Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Meningioma Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Meningioma Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Meningioma Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Meningioma Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Meningioma Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Meningioma Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Meningioma Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Meningioma Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Meningioma Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Meningioma Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Meningioma Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Arno Therapeutics Inc
  2. 8.1.1 Arno Therapeutics Inc Company Information
  3. 8.1.2 Arno Therapeutics Inc Business Overview
  4. 8.1.3 Arno Therapeutics Inc Meningioma Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Arno Therapeutics Inc Meningioma Drug Product Portfolio
  6. 8.1.5 Arno Therapeutics Inc Recent Developments
  7. 8.2 Boehringer Ingelheim GmbH
  8. 8.2.1 Boehringer Ingelheim GmbH Company Information
  9. 8.2.2 Boehringer Ingelheim GmbH Business Overview
  10. 8.2.3 Boehringer Ingelheim GmbH Meningioma Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Boehringer Ingelheim GmbH Meningioma Drug Product Portfolio
  12. 8.2.5 Boehringer Ingelheim GmbH Recent Developments
  13. 8.3 Genentech Inc
  14. 8.3.1 Genentech Inc Company Information
  15. 8.3.2 Genentech Inc Business Overview
  16. 8.3.3 Genentech Inc Meningioma Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Genentech Inc Meningioma Drug Product Portfolio
  18. 8.3.5 Genentech Inc Recent Developments
  19. 8.4 Merck KGaA
  20. 8.4.1 Merck KGaA Company Information
  21. 8.4.2 Merck KGaA Business Overview
  22. 8.4.3 Merck KGaA Meningioma Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Merck KGaA Meningioma Drug Product Portfolio
  24. 8.4.5 Merck KGaA Recent Developments
  25. 8.5 Ono Pharmaceutical Co Ltd
  26. 8.5.1 Ono Pharmaceutical Co Ltd Company Information
  27. 8.5.2 Ono Pharmaceutical Co Ltd Business Overview
  28. 8.5.3 Ono Pharmaceutical Co Ltd Meningioma Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Ono Pharmaceutical Co Ltd Meningioma Drug Product Portfolio
  30. 8.5.5 Ono Pharmaceutical Co Ltd Recent Developments
  31. 8.6 Pharma Mar SA
  32. 8.6.1 Pharma Mar SA Company Information
  33. 8.6.2 Pharma Mar SA Business Overview
  34. 8.6.3 Pharma Mar SA Meningioma Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pharma Mar SA Meningioma Drug Product Portfolio
  36. 8.6.5 Pharma Mar SA Recent Developments
  37. 8.7 Progenics Pharmaceuticals Inc
  38. 8.7.1 Progenics Pharmaceuticals Inc Company Information
  39. 8.7.2 Progenics Pharmaceuticals Inc Business Overview
  40. 8.7.3 Progenics Pharmaceuticals Inc Meningioma Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Progenics Pharmaceuticals Inc Meningioma Drug Product Portfolio
  42. 8.7.5 Progenics Pharmaceuticals Inc Recent Developments
  43. 8.8 AstraZeneca Plc
  44. 8.8.1 AstraZeneca Plc Company Information
  45. 8.8.2 AstraZeneca Plc Business Overview
  46. 8.8.3 AstraZeneca Plc Meningioma Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 AstraZeneca Plc Meningioma Drug Product Portfolio
  48. 8.8.5 AstraZeneca Plc Recent Developments
  49. 8.9 GlaxoSmithKline Plc
  50. 8.9.1 GlaxoSmithKline Plc Company Information
  51. 8.9.2 GlaxoSmithKline Plc Business Overview
  52. 8.9.3 GlaxoSmithKline Plc Meningioma Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 GlaxoSmithKline Plc Meningioma Drug Product Portfolio
  54. 8.9.5 GlaxoSmithKline Plc Recent Developments
  55. 8.10 Eli Lilly and Co
  56. 8.10.1 Eli Lilly and Co Company Information
  57. 8.10.2 Eli Lilly and Co Business Overview
  58. 8.10.3 Eli Lilly and Co Meningioma Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Eli Lilly and Co Meningioma Drug Product Portfolio
  60. 8.10.5 Eli Lilly and Co Recent Developments
  61. 8.11 Merck & Co Inc
  62. 8.11.1 Merck & Co Inc Company Information
  63. 8.11.2 Merck & Co Inc Business Overview
  64. 8.11.3 Merck & Co Inc Meningioma Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Merck & Co Inc Meningioma Drug Product Portfolio
  66. 8.11.5 Merck & Co Inc Recent Developments
  67. 8.12 Novartis AG
  68. 8.12.1 Novartis AG Company Information
  69. 8.12.2 Novartis AG Business Overview
  70. 8.12.3 Novartis AG Meningioma Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Novartis AG Meningioma Drug Product Portfolio
  72. 8.12.5 Novartis AG Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Meningioma Drug Value Chain Analysis
  2. 9.1.1 Meningioma Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Meningioma Drug Sales Mode & Process
  6. 9.2 Meningioma Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Meningioma Drug Distributors
  9. 9.2.3 Meningioma Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst